Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

Pratley, Richard E.; Nauck, Michael A.; Bailey, Timothy S.; Montanya, Eduard; Cuddihy, Robert; Filetti, Sébastiano; Thomsen, Anne Bloch; Søndergaard, Rie Elvang; Davies, Melanie J.

doi:10.1016/s0140-6736(10)60307-8

Cited by 535 publications

(746 citation statements)

References 24 publications

Supporting

Mentioning

681

Contrasting

Unclassified

Order By: Relevance

“…However, in the present review, only head-to-head trials vs active comparators are presented in brief. Gliptins have also been compared with SUs (glimepiride, glipizide, gliclazide) [27][28][29][30][31][32][33][34], TZDs (pioglitazone 30 mg, rosiglitazone 8 mg) [35][36][37][38][39] and GLP-1 receptor agonists (exenatide, liraglutide) [36,40,41]. However, only one head-to-head study compared two different DPP-4 inhibitors in the same trial: saxagliptin 5 mg with sitaglitptin 100 mg as add-ons to basal metformin therapy [42].…”

Section: Gliptins Combined With Metforminmentioning

confidence: 99%

“…However, head-to-head comparisons of the two therapies are scarce, and only one DPP-4 (sitagliptin) has been so evaluated. Two trials compared sitagliptin 100 mg vs exenatide either twice daily [76] or once weekly [36], and a further trial compared sitagliptin 100 mg with liraglutide once daily [40] (Table 2). …”

Section: Dpp-4 Inhibitors Vs Glp-1 Receptor Agonistsmentioning

confidence: 99%

“…Also, an extension of the study showed that patients who switched to once-weekly exenatide from daily sitagliptin had improved or sustained glycaemic control (HbA 1c -0.3%) and weight loss (-1.1 %) [77]. In a 24-week prospective trial comparing treatment with liraglutide (1.2 or 1.8 mg once daily) vs sitagliptin 100 mg in metformin-treated patients with T2DM, reductions in HbA 1c and body weight were significantly greater with both dosages of liraglutide than with sitagliptin, but at the cost of an increased incidence of minor sideeffects such as nausea and vomiting (Table 2) [40]. Incidences of hypoglycaemic events were low (5%) and similar in all treatment groups.…”

Section: Dpp-4 Inhibitors Vs Glp-1 Receptor Agonistsmentioning

confidence: 99%

See 2 more Smart Citations

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

Scheen¹

2012

Diabetes & Metabolism

174

124

View full text Add to dashboard Cite

Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering comparators in drug-naive patients have demonstrated that DPP-4 inhibitors exert slightly less pronounced HbA 1c reduction than metformin (with the advantage of better gastrointestinal tolerability) and similar glucose-lowering effects as with a thiazolidinedione (TZD; with the advantage of no weight gain). In metformin-treated patients, gliptins were associated with similar HbA 1c reductions compared with a sulphonylurea (SU; with the advantage of no weight gain, considerably fewer hypoglycaemic episodes and no need for titration) and a TZD (with the advantage of no weight gain and better overall tolerability). DPP-4 inhibitors also exert clinically relevant glucose-lowering effects compared with a placebo in patients treated with SU or TZD (of potential interest when metformin is either not tolerated or contraindicated), and as oral triple therapy with a good tolerability profile when added to a metformin-SU or pioglitazone-SU combination. Several clinical trials also showed a consistent reduction in HbA 1c when DPP-4 inhibitors were added to basal insulin therapy, with no increased risk of hypoglycaemia. Because of the complex pathophysiology of type 2 diabetes and the complementary actions of glucose-lowering agents, initial combination of a DPP-4 inhibitor with either metformin or a glitazone may be applied in drug-naive patients, resulting in greater efficacy and similar safety compared with either drug as monotherapy. However, DPP-4 inhibitors were less effective than GLP-1 receptor agonists for reducing HbA 1c and body weight, but offer the advantage of being easier to use (oral instead of injected administration) and lower in cost. Only one head-tohead trial demonstrated the non-inferiority of saxagliptin vs sitagliptin. Clearly, more trials of direct comparisons between different incretin-based therapies are needed. Because of their pharmacokinetic characteristics, pharmacodynamic properties (glucose-dependent glucose-lowering effect) and good overall tolerability profile, DPP-4 inhibitors may have a key role to play in patients with renal impairment and in the elderly. The role of DPP-4 inhibitors in the therapeutic armamentarium of type 2 diabetes is rapidly evolving as their potential strengths and weaknesses become better defined mainly through controlled clinical trials. Keywords:Clinical trial-DPP-4 inhibitor; Alogliptin; Linagliptin; Saxagliptin; Sitagliptin; Vildagliptin; Type 2 diabetes mellitus; Review Résumé Les inhibiteurs de la DPP-4 dans le traitement du diabète de type 2 : revue critique des essais cliniques contrôlés.Les inhibiteurs de la dipeptidylpeptidase-4 (DPP-4) offrent de nouvelles options pour le traitement du diabète de type 2. Des comparaisons directes avec d'autres médicaments antidiabétiques chez des patients naïfs de tout traitement ont démontré que les inhibiteurs de la DPP-4 étaient un peu moins puissants pour diminuer ...

show abstract

Section: Gliptins Combined With Metforminmentioning

confidence: 99%

Section: Dpp-4 Inhibitors Vs Glp-1 Receptor Agonistsmentioning

confidence: 99%

Section: Dpp-4 Inhibitors Vs Glp-1 Receptor Agonistsmentioning

confidence: 99%

See 1 more Smart Citation

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

Scheen¹

2012

Diabetes & Metabolism

174

124

View full text Add to dashboard Cite

show abstract

“…GLP-1RAs have shown either no or a small effect on heart rate (0-2 bpm), whereas long-acting GLP-1RAs produced a moderate increase (2-5 bpm) [15,23,24]. Both long-and short-acting GLP-1RAs reduce blood pressure.…”

Section: Glp-1ras and CV Variablesmentioning

confidence: 99%

Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus

Aronson

2013

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

“…These observations have never been reported in Caucasians, and it might be that some Japanese diabetic patients have an ethnical manifestation of potentially extreme sensitivity to incretin‐based therapy with the administration of sulfonylureas. Previous studies showed the superiority of liraglutide to dipeptidyl peptidase‐4 inhibitor in lowering glycemia 14 . It is now of clinical interest to determine which patients can tolerate the combination of sulfonylureas with liraglutide, and which patients are sufficiently controlled with liraglutide alone when we change treatment from BOT in Japanese diabetic patients.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal‐supported oral therapy

Takahara

Shiraiwa²,

Ohtoshi³

et al. 2012

J of Diabetes Invest

View full text Add to dashboard Cite

(J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00223.x, 2012) Aims/Introduction: We assessed the efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal‐supported oral therapy (BOT).Materials and Methods: We retrospectively analyzed the data of 37 patients who had postprandial hyperglycemia (≥10.0 mmol/L) with BOT (long‐acting insulin plus glimepiride) with their insulin titrated enough to keep preprandial glycemia <7.2 mmol/L, and who had their treatment changed to liraglutide monotherapy, with the subsequent addition of glimepiride, when required. Those who achieved the glycemic target at all points (preprandial glycemia <7.2 mmol/L and postprandial glycemia <10.0 mmol/L) were regarded as responders and the efficacy of liraglutide therapy was assessed. We also explored the predictive clinical characteristics associated with its efficacy.Results: Daily doses of insulin and glimepiride with BOT were 14 ± 9 units and 1.5 ± 0.9 mg, respectively. After the change to liraglutide therapy, 37% of the patients appeared to be responders to the therapy, whereas 12% had their glycemic control rather deteriorated. Efficacy of liraglutide therapy was significantly associated with baseline insulin dosage and post‐breakfast glycemia with BOT. The C‐statistic of the model was calculated to be 0.90.Conclusions: There were responders and non‐responders to liraglutide therapy in Japanese BOT failures. It is likely that baseline insulin dosage and post‐breakfast glycemia with BOT are clinically useful indicators for the efficacy of liraglutide therapy.

show abstract

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

Cited by 535 publications

References 24 publications

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus

Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal‐supported oral therapy

Contact Info

Product

Resources

About